- Home
- ELS vs GMAB Comparison
ELS vs GMAB Comparison
Compare ELS & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELS | GMAB |
|---|---|---|
| Founded | 1992 | 1999 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 17.4B |
| IPO Year | 1993 | N/A |
Fundamental Metrics
Financial Performance| Metric | ELS | GMAB |
|---|---|---|
| Price | $62.00 | $31.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 6 |
| Target Price | ★ $71.23 | $40.40 |
| AVG Volume (30 Days) | ★ 1.6M | 1.4M |
| Earning Date | 01-26-2026 | 11-06-2025 |
| Dividend Yield | ★ 3.32% | N/A |
| EPS Growth | 2.36 | ★ 132.41 |
| EPS | 1.99 | ★ 25.10 |
| Revenue | $1,535,911,000.00 | ★ $3,845,670,022.00 |
| Revenue This Year | $1.02 | $24.85 |
| Revenue Next Year | $4.52 | $16.67 |
| P/E Ratio | $31.13 | ★ $1.25 |
| Revenue Growth | 0.93 | ★ 29.57 |
| 52 Week Low | $58.15 | $17.24 |
| 52 Week High | $70.35 | $33.65 |
Technical Indicators
Market Signals| Indicator | ELS | GMAB |
|---|---|---|
| Relative Strength Index (RSI) | 53.33 | 52.06 |
| Support Level | $59.89 | $30.81 |
| Resistance Level | $62.84 | $32.51 |
| Average True Range (ATR) | 1.05 | 0.65 |
| MACD | -0.12 | -0.03 |
| Stochastic Oscillator | 56.14 | 31.94 |
Price Performance
Historical ComparisonAbout ELS Equity Lifestyle Properties Inc.
Equity Lifestyle Properties is a residential REIT that focuses on owning manufactured housing, residential vehicle communities, and marinas. The company currently has a portfolio of 455 properties across the U.S. with a higher concentration in the Sunbelt region with 38% of the company's properties located in Florida, 12% in Arizona, and 8% in California. Equity Lifestyle targets owning properties in attractive retirement destinations with over 70% of the company's properties either being age-restricted or having an average resident age over 55.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.